TTD | Drug: D05BLN

Drug General Information
Drug ID	D05BLN
Former ID	DIB006780
Drug Name	MGCD516
Indication	Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]		Phase 1	[524880]
Company	Mirati therapeutics
Target and Pathway
Target(s)	Hepatocyte growth factor receptor	Target Info	Inhibitor	[531337]
Target(s)	Proto-oncogene tyrosine-protein kinase receptor ret	Target Info	Inhibitor	[531337]
KEGG Pathway	Ras signaling pathway
	Rap1 signaling pathway
	Cytokine-cytokine receptor interaction
	Endocytosis
	PI3K-Akt signaling pathway
	Axon guidance
	Focal adhesion
	Adherens junction
	Bacterial invasion of epithelial cells
	Epithelial cell signaling in Helicobacter pylori infection
	Malaria
	Pathways in cancer
	Transcriptional misregulation in cancer
	Proteoglycans in cancer
	MicroRNAs in cancer
	Renal cell carcinoma
	Melanoma
	Central carbon metabolism in cancerhsa04144:Endocytosis
	Thyroid cancer
	Central carbon metabolism in cancer
Pathway Interaction Database	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
	Arf6 signaling events
	Signaling events mediated by TCPTP
	Posttranslational regulation of adherens junction stability and dissassembly
	Direct p53 effectors
	Syndecan-1-mediated signaling events
	Stabilization and expansion of the E-cadherin adherens junction
	a6b1 and a6b4 Integrin signaling
	FGF signaling pathway
	Regulation of retinoblastoma proteinret_pathway:Signaling events regulated by Ret tyrosine kinase
Reactome	Sema4D mediated inhibition of cell attachment and migration
WikiPathways	TGF beta Signaling Pathway
	Signaling of Hepatocyte Growth Factor Receptor
	Focal Adhesion
	Extracellular vesicle-mediated signaling in recipient cells
	Signaling Pathways in Glioblastoma
	miR-targeted genes in squamous cell - TarBase
	miR-targeted genes in muscle cell - TarBase
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
	Semaphorin interactionsWP706:SIDS Susceptibility Pathways
	Dopaminergic Neurogenesis
References
Ref 524880	ClinicalTrials.gov (NCT02219711) Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer. U.S. National Institutes of Health.
Ref 531337	Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res. 2011 May 1;17(9):2638-45.

Drug Information